Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer

Drift, Miep A. van der; Hol, Bernard; Klaassen, Corné H. W.; Prinsen, Clemens; Aarssen, Yvonne A.W.G. van; Donders, Rogier; Stappen, J. W. J. van der; Dekhuijzen, P.N.R.; Heijden, Erik H F M van der; Thunnissen, Erik

doi:10.1016/j.lungcan.2009.06.021

Cited by 73 publications

(66 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostic monitoring of drug delivery nanoparticle levels [8][9][10], identification of cell-free circulating (cfc) DNA/RNA and other nanoparticulate biomarkers [11][12][13][14][15], and detection of pathogens in clinical and environmental samples [16] are examples where low level detection of analytes are of extreme importance. Common wide field epifluorescent microscopes generally lack the resolution and sensitivity to detect low levels of nanoparticulates in biological and clinical samples such as blood and plasma.…”

Section: Introductionmentioning

confidence: 99%

Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays

McCanna¹,

Sonnenberg²,

Heller³

2013

Journal of Biophotonics

View full text Add to dashboard Cite

Common epifluorescent microscopy lacks the sensitivity to detect low levels of analytes directly in clinical samples, such as drug delivery nanoparticles or disease related DNA biomarkers. Advanced systems such as confocal microscopes may improve detection, but several factors limit their applications. This study now demonstrates that combining an epifluorescent microscope with a dielectrophoretic (DEP) microelectrode array device enables the detection of nanoparticles and DNA biomarkers at clinically relevant levels. Using DEP microarray devices, nanoparticles and DNA biomarkers are rapidly isolated and concentrated onto specific microscopic locations where they are easily detected by epifluorescent microscopy. In this study, 40nm nanoparticles were detected down to 2–3 × 103/ul levels and DNA was detected down to the 200 pg/ml level. The synergy of epifluorescent microscopy and DEP microarray devices provides a new paradigm for DNA biomarker diagnostics and the monitoring of drug delivery nanoparticle concentrations. (© 2014 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)

show abstract

Section: Introductionmentioning

confidence: 99%

Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays

McCanna¹,

Sonnenberg²,

Heller³

2013

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…Results show that a high circulating DNA concentration correlates with poor survival of NSCLC patients compared with low DNA concentration (16.8 months vs. 22.4 months; p=0.02) [49]. van der Drift et al [48] in their study demonstrated that overall survival for the NSCLC patients with circulating DNA concentration ≥32 ng/ml was significantly shorter compared to NSCLC patients with lower circulating DNA concentration (11.8 months vs. 21.5 months; p=0.03). A DNA cut-off level of >32 ng/ml differentiated with a specificity of 52% and sensitivity of 67%.…”

Section: Circulating Tumor Dnamentioning

confidence: 97%

“…An increased circulating DNA concentration in serum or plasma is thought to originate from cancer cells through such processes as apoptosis, necrosis or circulating tumor cells lysis [48,49]. Higher circulating DNA levels are identified in NSCLC patients with disease progression compared with NSCLC patients without disease progression (110.5 ng/ml vs. 82.6 ng/ml; p<0.001) [50].…”

Section: Circulating Tumor Dnamentioning

confidence: 99%

The role of genetic and other biomarkers in NSCLC prognosis

et al. 2014

View full text Add to dashboard Cite

AbstractThe development of non-small-cell lung cancer (NSCLC) is a multistep process, which is triggered and maintained by various factors. Many steps of non-small-cell lung carcinogenesis, risk factors and biomarkers have been identified; however no consistent model has been established of personalized medicine for these patients. Distinct various gene expression, products of mutated genes and other markers such as circulating nucleic acids or tumor cells has been proven to be potential biomarkers of non-small cell lung cancer as well as potential targets for new treatment strategies. This article will highlight promising biomarkers in non-small cell lung cancer prognosis.

show abstract

“…Such studies have indicated a good correlation between restricted expression at the tissue level and the occurrence of detectable levels of candidate biomarkers in serum/plasma DNA. In this connection, the circulating methylated DNA approach has been applied as a biomarker in various forms of cancer, including pancreatic [19,20,24,25], ovarian [26][27][28][29], prostate carcinoma [30][31][32][33][34], hepatocellular carcinoma [35][36][37][38], esophageal adenocarcinoma [39,40], colorectal carcinoma [8,41,42], breast [3,[43][44][45], head and neck squamous cell carcinoma [46][47][48], non-Hodgkin lymphoma [49], and lung cancer [10,16,18,[50][51][52].…”

Section: Altered Epigenetic Regulation Assessed By the Cell-free Circmentioning

confidence: 99%

Circulating DNA as a Biomarker for Early Detection of Cancer: A Brief Update with an Emphasis on Lung Cancer~!2010-06-09~!2010-08-03~!2010-09-06~!

Cabral¹

2010

TOLCJ

View full text Add to dashboard Cite

Abstract:In most cases, early detection and treatment of cancer are prerequisites for full recovery. However, its early detection continues to be extremely difficult since its characteristic symptoms rarely manifest at the onset of disease. The development of highly sensitive, specific biomarkers also capable of reflecting pathological changes is, therefore, of the upmost importance. Lung cancer, for example, is most frequently diagnosed during the late metastatic stage so that, as a result, malignant neoplasms in the lung are among the leading causes of cancer-related deaths worldwide. Circulating DNA is a non-invasive diagnostic assay that has been greatly improved for the purposes of diagnosis, prognosis, and treatment of cancer. In the current review, we discuss recent data concerning circulating tumor-derived DNA as a tool for early detection, diagnosis, and follow-up. Given the scope of this review, the focus will be on lung cancer, one of the most prolific and lethal cancers affecting humanity today.

show abstract

Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer

Cited by 73 publications

References 32 publications

Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays

Low level epifluorescent detection of nanoparticles and DNA on dielectrophoretic microarrays

The role of genetic and other biomarkers in NSCLC prognosis

Circulating DNA as a Biomarker for Early Detection of Cancer: A Brief Update with an Emphasis on Lung Cancer~!2010-06-09~!2010-08-03~!2010-09-06~!

Contact Info

Product

Resources

About